Educational information, not medical advice — ask your doctor or midwife.
Matrixyl 3000 is a proprietary cosmetic peptide complex developed by Sederma, combining two signaling peptides — Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7. The palmitic acid tail attached to each peptide helps them penetrate the outer skin barrier and reach the deeper dermal layers where collagen-producing cells live. It was developed as an alternative to retinol for people who want anti-aging skin benefits without the irritation.
The two peptides work as a team. Palmitoyl Tripeptide-1 mimics a fragment of collagen breakdown, which tells the skin that collagen has been lost and triggers fibroblast cells to make more. Palmitoyl Tetrapeptide-7 helps calm low-grade skin inflammation that accelerates aging, reducing the signals that tell the body to break down existing collagen. Together, they nudge the skin into a repair and rebuilding cycle.
Matrixyl 3000 is exclusively a topical ingredient — it is not taken orally. It is found in serums (highest concentration, fastest delivery), moisturizers (good for daily use), eye creams (formulated for delicate periocular skin), and ampoules (short-term intensive treatments). Look for it listed near the top of the ingredient list for meaningful concentrations — effective products typically contain 3–8 ppm of the active peptide complex.
Matrixyl was first introduced by Sederma (France) in the early 2000s, with Matrixyl 3000 — the improved two-peptide version — launched around 2006. It quickly became one of the most widely used anti-aging peptide complexes in prestige skincare, popularized in part by independent clinical testing published in peer-reviewed dermatology literature.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.